Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form

Abstract

Methods for treating vasomotor symptoms associated with menopause are described.

1 .- 34 . (canceled) 
     
     
         35 . A titration regimen for treating a subject experiencing menopause-related vasomotor symptoms, comprising:
 administering a first total daily dose of gabapentin in a dosage form for a first time period;   administering a second total daily dose of gabapentin in the dosage form for a second time period;   wherein the second total daily dose is greater than the first total daily dose; and   wherein the dosage form comprises a hydrophilic polymer, wherein after administration the dosage form swells to a size that is retained in the stomach of the subject.   
     
     
         36 . The regimen of  claim 35 , further comprising administering a third total daily dose of gabapentin in the dosage form for a third period of time. 
     
     
         37 . The regimen of  claim 35 , wherein administering the first total daily dose of gabapentin comprises administering the first total daily dose once per day. 
     
     
         38 . The regimen of  claim 37 , wherein the first total daily dose is administered in the evening. 
     
     
         39 . The regimen of  claim 35 , wherein the first total daily dose is between about 600 mg and 1200 mg. 
     
     
         40 . The regimen of  claim 35 , wherein the first total daily dose is about 600 mg. 
     
     
         41 . The regimen of  claim 35 , wherein the first period of time is about 1 to 3 days. 
     
     
         42 . The regimen of  claim 35 , wherein the first period of time is about 3 days. 
     
     
         43 . The regimen of  claim 35 , wherein administering the second total daily dose comprises administering the second total daily dose once per day. 
     
     
         44 . The regimen of  claim 43 , wherein the second total daily dose is administered in the evening. 
     
     
         45 . The regimen of  claim 35 , wherein the second total daily dose is between about 800 mg and 1500 mg. 
     
     
         46 . The regimen of  claim 35 , wherein the second total daily dose is about 1200 mg. 
     
     
         47 . The regimen of  claim 35 , wherein the second period of time is between about 2 to 4 days. 
     
     
         48 . The regimen of  claim 35 , wherein the second period of time is about 3 days. 
     
     
         49 . The regimen of  claim 36 , wherein the third total daily dose is administered as a first and a second dose. 
     
     
         50 . The regimen of  claim 36 , wherein the third total daily dose is between about 600 mg and 2400 mg. 
     
     
         51 . The regimen of  claim 36 , wherein the third total daily dose is about 1800 mg. 
     
     
         52 . The regimen of  claim 49 , wherein the first dose is 600 mg administered in the morning and the second dose is 1200 mg administered in the evening. 
     
     
         53 . The regimen of  claim 36 , wherein the third period of time is 2 or more days.